The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
More top news
The new measures would mirror childcare vouchers and see workers sacrifice some of their salary to benefit.
Google, Facebook and Twitter could face multi-million pound fines over their failure to remove illegal content, MPs say.
Staffing levels and worsening pay are to blame, according to the report by the Health Foundation.